These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 29297746)

  • 21. Safety, immunogenicity and infectivity of new live attenuated influenza vaccines.
    Isakova-Sivak I; Rudenko L
    Expert Rev Vaccines; 2015; 14(10):1313-29. PubMed ID: 26289975
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inactivated influenza virus vaccines in children.
    Ruben FL
    Clin Infect Dis; 2004 Mar; 38(5):678-88. PubMed ID: 14986252
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A prospective, randomized, open-label trial comparing the safety and efficacy of trivalent live attenuated and inactivated influenza vaccines in adults 60 years of age and older.
    Forrest BD; Steele AD; Hiemstra L; Rappaport R; Ambrose CS; Gruber WC
    Vaccine; 2011 May; 29(20):3633-9. PubMed ID: 21440036
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections.
    Ashkenazi S; Vertruyen A; Arístegui J; Esposito S; McKeith DD; Klemola T; Biolek J; Kühr J; Bujnowski T; Desgrandchamps D; Cheng SM; Skinner J; Gruber WC; Forrest BD;
    Pediatr Infect Dis J; 2006 Oct; 25(10):870-9. PubMed ID: 17006279
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A comparative study of live and inactivated influenza vaccines: the organization of the observation and the results of a study of their reactogenicity and immunogenicity].
    Slepushkin AN; Rudenko LG; Kendal AP; Monto AS; Beliaev AL; Burtseva EI; Grigor'eva EP; Obrosova-Serova NP; Ivanova VT; Bragina VE
    Vopr Virusol; 1994; 39(3):129-31. PubMed ID: 8091754
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The safety and efficacy of live attenuated influenza vaccine in young children with asthma or prior wheezing.
    Ambrose CS; Dubovsky F; Yi T; Belshe RB; Ashkenazi S
    Eur J Clin Microbiol Infect Dis; 2012 Oct; 31(10):2549-57. PubMed ID: 22410646
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A double-blind, randomized controlled trial to evaluate the safety and immunogenicity of an intranasally administered trivalent inactivated influenza vaccine with the adjuvant LTh(αK): A phase II study.
    Pan SC; Hsu WT; Lee WS; Wang NC; Chen TJ; Liu MC; Pai HC; Hsu YS; Chang M; Hsieh SM
    Vaccine; 2020 Jan; 38(5):1048-1056. PubMed ID: 31812463
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity and safety of trivalent inactivated influenza vaccine: a randomized, double-blind, multi-center, phase 3 clinical trial in a vaccine-limited country.
    Song JY; Cheong HJ; Woo HJ; Wie SH; Lee JS; Chung MH; Kim YR; Jung SI; Park KH; Kim TH; Uh ST; Kim WJ
    J Korean Med Sci; 2011 Feb; 26(2):191-5. PubMed ID: 21286008
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety of guidelines recommending live attenuated influenza vaccine for routine use in children and adolescents with asthma.
    Nordin JD; Vazquez-Benitez G; Olsen A; Kuckler LC; Gao AY; Kharbanda EO
    Vaccine; 2019 Jul; 37(30):4055-4060. PubMed ID: 31196683
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Report of the 7th meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials, World Health Organization, Geneva, 17-18 February 2011.
    Girard MP; Katz JM; Pervikov Y; Hombach J; Tam JS
    Vaccine; 2011 Oct; 29(44):7579-86. PubMed ID: 21856358
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Understanding Immunity in Children Vaccinated With Live Attenuated Influenza Vaccine.
    Shannon I; White CL; Nayak JL
    J Pediatric Infect Dis Soc; 2020 Mar; 9(Supplement_1):S10-S14. PubMed ID: 31848606
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity, safety, and tolerability of two trivalent subunit inactivated influenza vaccines: a phase III, observer-blind, randomized, controlled multicenter study.
    Tregnaghi MW; Stamboulian D; Vanadía PC; Tregnaghi JP; Calvari M; Fragapane E; Casula D; Pellegrini M; Groth N
    Viral Immunol; 2012 Jun; 25(3):216-25. PubMed ID: 22691101
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized Comparison of Immunogenicity and Safety of Quadrivalent Recombinant Versus Inactivated Influenza Vaccine in Healthy Adults 18-49 Years of Age.
    Dunkle LM; Izikson R; Patriarca PA; Goldenthal KL; Muse D; Cox MMJ
    J Infect Dis; 2017 Dec; 216(10):1219-1226. PubMed ID: 28968871
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent changes in influenza epidemiology and vaccination recommendations.
    Zimmerman RK
    J Fam Pract; 2005 Jan; 54(1 Suppl):S1-8. PubMed ID: 15623391
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessing Fever Frequency After Pediatric Live Attenuated Versus Inactivated Influenza Vaccination.
    Stockwell MS; Broder KR; Lewis P; Jakob K; Iqbal S; Fernandez N; Sharma D; Barrett A; LaRussa P
    J Pediatric Infect Dis Soc; 2017 Sep; 6(3):e7-e14. PubMed ID: 27302328
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial.
    Cadorna-Carlos JB; Nolan T; Borja-Tabora CF; Santos J; Montalban MC; de Looze FJ; Eizenberg P; Hall S; Dupuy M; Hutagalung Y; Pépin S; Saville M
    Vaccine; 2015 May; 33(21):2485-92. PubMed ID: 25843270
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and immunogenicity of a live attenuated influenza H5 candidate vaccine strain A/17/turkey/Turkey/05/133 H5N2 and its priming effects for potential pre-pandemic use: a randomised, double-blind, placebo-controlled trial.
    Pitisuttithum P; Boonnak K; Chamnanchanunt S; Puthavathana P; Luvira V; Lerdsamran H; Kaewkungwal J; Lawpoolsri S; Thanachartwet V; Silachamroon U; Masamae W; Schuetz A; Wirachwong P; Thirapakpoomanunt S; Rudenko L; Sparrow E; Friede M; Kieny MP
    Lancet Infect Dis; 2017 Aug; 17(8):833-842. PubMed ID: 28533093
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity and safety of inactivated influenza virus vaccine in young children in 2003-2004.
    Mitchell DK; Ruben FL; Gravenstein S
    Pediatr Infect Dis J; 2005 Oct; 24(10):925-7. PubMed ID: 16220095
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and immunogenicity of unadjuvanted subvirion monovalent inactivated influenza H3N2 variant (H3N2v) vaccine in children and adolescents.
    Munoz FM; Anderson EJ; Bernstein DI; Harrison CJ; Pahud B; Anderson E; Creech CB; Berry AA; Kotloff KL; Walter EB; Atmar RL; Bellamy AR; Chang S; Keitel WA
    Vaccine; 2019 Aug; 37(36):5161-5170. PubMed ID: 31375440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 Dec; 58(48):1351-6. PubMed ID: 20010511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.